Cargando…
Oral Alitretinoin for Patients with Refractory Prurigo
Background: prurigo is a chronic skin disorder associated with a history of chronic pruritus. The pathogenesis of prurigo is largely unknown and the treatment of prurigo is unsatisfactory and challenging. Conventional systemic treatments may be beneficial; however, their possible side effects and po...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7695266/ https://www.ncbi.nlm.nih.gov/pubmed/33182351 http://dx.doi.org/10.3390/medicina56110599 |
_version_ | 1783615149129596928 |
---|---|
author | Chung, Bo Young Um, Ji Young Kang, Seok Young Jung, Min Je Kim, Jin Cheol Kwak, In-Suk Park, Chun Wook Kim, Hye One |
author_facet | Chung, Bo Young Um, Ji Young Kang, Seok Young Jung, Min Je Kim, Jin Cheol Kwak, In-Suk Park, Chun Wook Kim, Hye One |
author_sort | Chung, Bo Young |
collection | PubMed |
description | Background: prurigo is a chronic skin disorder associated with a history of chronic pruritus. The pathogenesis of prurigo is largely unknown and the treatment of prurigo is unsatisfactory and challenging. Conventional systemic treatments may be beneficial; however, their possible side effects and possible transient efficacy is still a problem. We aimed to present the clinical course and effect of treatment with alitretinoin on patients with prurigo nodularis initially treated with conventional treatments like oral antihistamine, cyclosporine, and phototherapy. Methods: all the patients had prurigo nodularis refractory to conventional treatment. Their medical records included demographic features, past medical history, duration of disease, and treatment modalities; and the clinical courses of the patients were reviewed for this retrospective study. We evaluated patient pruritus and skin lesions for the duration. Results: we present reports involving 10 patients with refractory prurigo. All the patients in our cases were treated with oral alitretinoin after previous treatments and reported the improvement of skin lesions and pruritus within 2 weeks to 3 months. Conclusions: we suggest that oral alitretinoin may be an effective and well tolerated treatment option for patients with intractable prurigo. Further clinical studies are warranted to confirm the long-lasting efficacy and safety of alitretinoin for treating patients with prurigo. |
format | Online Article Text |
id | pubmed-7695266 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-76952662020-11-28 Oral Alitretinoin for Patients with Refractory Prurigo Chung, Bo Young Um, Ji Young Kang, Seok Young Jung, Min Je Kim, Jin Cheol Kwak, In-Suk Park, Chun Wook Kim, Hye One Medicina (Kaunas) Article Background: prurigo is a chronic skin disorder associated with a history of chronic pruritus. The pathogenesis of prurigo is largely unknown and the treatment of prurigo is unsatisfactory and challenging. Conventional systemic treatments may be beneficial; however, their possible side effects and possible transient efficacy is still a problem. We aimed to present the clinical course and effect of treatment with alitretinoin on patients with prurigo nodularis initially treated with conventional treatments like oral antihistamine, cyclosporine, and phototherapy. Methods: all the patients had prurigo nodularis refractory to conventional treatment. Their medical records included demographic features, past medical history, duration of disease, and treatment modalities; and the clinical courses of the patients were reviewed for this retrospective study. We evaluated patient pruritus and skin lesions for the duration. Results: we present reports involving 10 patients with refractory prurigo. All the patients in our cases were treated with oral alitretinoin after previous treatments and reported the improvement of skin lesions and pruritus within 2 weeks to 3 months. Conclusions: we suggest that oral alitretinoin may be an effective and well tolerated treatment option for patients with intractable prurigo. Further clinical studies are warranted to confirm the long-lasting efficacy and safety of alitretinoin for treating patients with prurigo. MDPI 2020-11-09 /pmc/articles/PMC7695266/ /pubmed/33182351 http://dx.doi.org/10.3390/medicina56110599 Text en © 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Chung, Bo Young Um, Ji Young Kang, Seok Young Jung, Min Je Kim, Jin Cheol Kwak, In-Suk Park, Chun Wook Kim, Hye One Oral Alitretinoin for Patients with Refractory Prurigo |
title | Oral Alitretinoin for Patients with Refractory Prurigo |
title_full | Oral Alitretinoin for Patients with Refractory Prurigo |
title_fullStr | Oral Alitretinoin for Patients with Refractory Prurigo |
title_full_unstemmed | Oral Alitretinoin for Patients with Refractory Prurigo |
title_short | Oral Alitretinoin for Patients with Refractory Prurigo |
title_sort | oral alitretinoin for patients with refractory prurigo |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7695266/ https://www.ncbi.nlm.nih.gov/pubmed/33182351 http://dx.doi.org/10.3390/medicina56110599 |
work_keys_str_mv | AT chungboyoung oralalitretinoinforpatientswithrefractoryprurigo AT umjiyoung oralalitretinoinforpatientswithrefractoryprurigo AT kangseokyoung oralalitretinoinforpatientswithrefractoryprurigo AT jungminje oralalitretinoinforpatientswithrefractoryprurigo AT kimjincheol oralalitretinoinforpatientswithrefractoryprurigo AT kwakinsuk oralalitretinoinforpatientswithrefractoryprurigo AT parkchunwook oralalitretinoinforpatientswithrefractoryprurigo AT kimhyeone oralalitretinoinforpatientswithrefractoryprurigo |